<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04009889</url>
  </required_header>
  <id_info>
    <org_study_id>HSO-PregO-2018</org_study_id>
    <nct_id>NCT04009889</nct_id>
  </id_info>
  <brief_title>Impact of Oral Probiotic Blend on Pregnancy Outcome</brief_title>
  <official_title>Double Blind,Randomized, Controlled Trial on Impact of Oral Probiotic Blend ( Lactobacillus Rhamnosus GG, L. Crispatus LBV88, L. Rhamnosus LBV96, L.Jensenii LBV116 and L. Gasseri LBV150 ) on Pregnancy Outcome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>i-Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>i-Health, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is, to investigate the effect of oral intake of Lactobacillus rhamnosus
      GG (ATCC 53103), Lactobacillus crispatus Lbv88, Lactobacillus rhamnosus Lbv96, Lactobacillus
      jensenii Lbv116 Lactobacillus gasseri Lbv150 on outcomes of pregnancy and microbiota and
      their interrelation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women aged &gt; 18 years in the &lt; 14th week of pregnancy willing to consume the study
      product once daily starting the day after V1 until delivery, complying with inclusion and
      exclusion criteria will be enrolled in the study.

      After enrollement subjects will be randomly and evenly assigned to one of the two test groups
      verum and placebo.

      The study population will be recruited in a screening examination ( G1 ) by gynaecologists
      from Kiel area.

      Primary target parameter of the study :

      HOMA-IRa value in week 24-28 (V2), which is based on glucose and insulin measures during the
      second oral glucose tolerance test (OGTT)

      Secondary target parameters :

      HOMA-IR value in week 36-40 , Alteration (V2 - V1) Δ HOMA-IR, Alteration (V2 - V1) Δ QUICKI
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2018</start_date>
  <completion_date type="Anticipated">May 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>N=162 pregnant women were randomly assigned to one of the 2 interventions: verum (Lactobacilli) or placebo</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HOMA-IR value in week 24-28</measure>
    <time_frame>measurement between 24-28 week of pregnancy</time_frame>
    <description>HOMA -IR is the product of insulin x glucose and describes the level of insulin resistance</description>
  </primary_outcome>
  <primary_outcome>
    <measure>HOMA-IR value in week 36-40</measure>
    <time_frame>measurement between 36-40 week of pregnancy</time_frame>
    <description>HOMA -IR is the product of insulin x glucose and describes the level of insulin resistance</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Gestational Diabetes Mellitus in Pregnancy</condition>
  <arm_group>
    <arm_group_label>verum</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>probiotic bland with 5 different lactobacilli</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>capsule containing a probiotic blend of 5 different Lactobacilli</intervention_name>
    <description>n=81 women (verum) starts befor end of pregnancy week 14 with consumption of 1 capsule daily until delivery.</description>
    <arm_group_label>verum</arm_group_label>
    <other_name>verum</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>capsule containing Microcrystalline Cellulose, Magnesium Stearate, Silicon Dioxide, but no probiotics.</intervention_name>
    <description>n=81 women (placebo) starts befor end of pregnancy week 14 with consumption of 1 capsule daily until delivery.</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  pregnant women aged &gt; 18 years in the &lt; 14 week of pregnancy

          -  willing to consume the study product during pregnancy ( V1 to delivery)

          -  willingness to abstain from probiotic food and supplements containing probiotics

          -  written informed consent

        Exclusion Criteria: Any of the following is regarded as a criterion for exclusion from
        enrollment in the study:

          1. Subjects currently enrolled in another clinical study

          2. Subjects having finished another clinical study within the last 4 weeks before
             inclusion

          3. Diabetes mellitus

          4. Acute metabolic disorder interfering with glucose metabolism

          5. Known cancer &lt; 5y ago

          6. Any ano-rectal infection, disease, surgery in the medical history or current which may
             have impact on microbiota

          7. Anus praeter

          8. Hypersensitivity, allergy or idiosyncratic reaction to any component of the test
             product

          9. Any disease or condition which might significantly compromise the hematopoietic,
             renal, endocrine, pulmonary, hepatic, gastrointestinal, cardiovascular, immunological,
             central nervous, dermatological or any other body system

         10. History of active hepatitis B and C

         11. History of HIV infection

         12. Regular medical treatment including OTC, which may have impact on the study aims (e.g.
             probiotics, antibiotic drugs, laxatives etc.)

         13. Major cognitive or psychiatric disorders

         14. Present drug abuse or alcoholism, reformed alcoholic Legal incapacity
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>pregnant women aged &gt; 18 years in the &lt; 14 week of pregnancy</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christiane Laue, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinical Research Center Kiel GmbH, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seema Mody</last_name>
    <phone>+1(860)894-1200</phone>
    <email>mody@dsm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Linnerth Barbara, PhD</last_name>
    <phone>+43/1/2350780</phone>
    <email>linnerth@HSO.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinical Research Center Kiel GmbH</name>
      <address>
        <city>Kiel</city>
        <state>Schleswig-Holstein</state>
        <zip>D-24118</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christiane Laue, MD</last_name>
      <phone>+49 431 5606</phone>
      <phone_ext>599</phone_ext>
      <email>c.laue@crc-kiel.de</email>
    </contact>
    <contact_backup>
      <last_name>Angelika Pannenbeckers, MD</last_name>
      <phone>+49 431 5606</phone>
      <phone_ext>870</phone_ext>
      <email>a.pannenbeckers@crc-kiel.de</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Pregnancy in Diabetics</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Silicon</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

